Latest news with #HIVAwareness
Japan Times
3 days ago
- Entertainment
- Japan Times
Hiraku Morilla: ‘Pride means respect for those who walked so we could run'
Hiraku Morilla, 40, has been the director of the Nakamura Keith Haring Collection since 2014, curating exhibitions and events about the American artist in the museum's facilities in Yamanashi Prefecture. Morilla advocates for the LGBTQ+ community through his work, combating discrimination and the stigmatization of HIV. 1. Can you tell us about your cultural background? I'm Japanese and Nuyorican (New York Puerto Rican). Expressing both Asian and Latino cultural identities at once has always felt disjointed — they're so far apart that embodying both never feels seamless. 2. How was your experience growing up in the Bronx? I was surrounded by rhythm and style. The way we spoke had cadence. The way we moved had rhythm. Manhattan was right there, but it felt like a different universe. We walked through metal detectors every morning at school. That's what it looks like when a system abandons the community. 3. What was it like being multiracial and queer? In my senior year of high school, I wrote a letter to myself that said, 'Do not come out as gay, no matter what.' I didn't want to be associated with the gay men who were mocked on TV, beat up in school or gossiped about. That changed when I started meeting them in real life. 4. How did your early life experiences shape your career? In Japan, New York becomes a kind of resume. But being Japanese and authentically New York throws people off. My New York isn't aesthetic or curated. It's survival. It's contradiction. It's lived, not borrowed. 5. How was working as a creative director under designer Patricia Field ('Sex and the City,' 'The Devil Wears Prada')? She valued authenticity. (Her brand) was a place where we had to prove ourselves — but we were family. Some of my pieces ended up on the cover of Vogue, on Beyoncé, on K-pop idols. Now it sounds surreal. Back then, it was just another Tuesday. 6. Why did you relocate to Japan? The catalyst was my mom's passing of pancreatic cancer in 2014. When I learned her condition had suddenly worsened, I packed up everything and flew straight to Japan to be with her. Just a few days after I arrived, she passed. 7. How are NYC and Tokyo different? What I like about living in Tokyo is the certainty. If I call a cab, it'll wait for me until I come out. In New York, if you take too long, it's gone. If the train's running late, Tokyo will tell you exactly how late. If you line up for something, you'll get in. If a package says 'open here' and you tear that part, it actually opens. 8. How did you end up as the director of the Nakamura Keith Haring Collection? Patricia suggested I visit the museum while I was in Japan. I did, and by chance I ran into the collector himself, Dr. (Kazuo) Nakamura. After a long conversation, he offered me a position. It was a rare chance to stay connected to New York while being in Japan. 9. What kinds of people visit the collection? All kinds. Older visitors often don't come for Haring; they just enjoy the area and happen to see a museum and drop by. Younger visitors tend to know Haring through K-pop. We also get a lot of Japanese celebrities and influencers. And of course, we have many LGBTQ+ visitors. We're not just the only Keith Haring museum in the world — we're also the only queer museum in Japan. 10. How does the location impact the visitor experience? Being in the mountains of Yamanashi — two hours from Tokyo by train or car — definitely affects our foot traffic. For some people, that distance feels like a burden. But at the same time, that distance creates something special. When you arrive, it's just you and Haring's work. No city noise, no gallery-hopping — just this one space, in nature, dedicated entirely to him. That isolation creates a kind of intimacy. It invites people to slow down, to really spend time with the art. 11. When did you first become aware of Haring? Growing up in New York, Haring was ubiquitous. As a kid, I automatically recognized his figures. Later, I also recognized him as a gay icon. But I really became aware of his depth as an artist and activist when I first visited the museum. "Haring's activism (is) not just relevant, but necessary," says Morilla of how the American artist's themes resonate in a contemporary Japanese context. | Koichi Nakazawa 12. What draws you to his work? The messaging. Take his faceless figures. They're simple, but emotionally loaded. That ability to express so much with so little is really powerful. Also, Haring's work is openly queer and deeply sex-positive. He's clearly attracted to masculinity, but not in a toxic way. That tenderness keeps drawing me in. 13. Why is Haring's legacy still relevant today? Unfortunately, we're still dealing with the same issues we were facing in the 1980s. But at the center of his work was always kindness. Keith would stand with you against racism, sexism, homophobia, transphobia, all of it. 14. How does your advocacy for LGBTQ+ issues and HIV awareness relate to Haring's legacy? Haring was openly gay and disclosed his HIV-positive status. In 1980s America, that meant putting himself at risk. In Japan, HIV infection rates are still increasing, and the government still hasn't recognized same-sex marriage. That makes Haring's activism not just relevant, but necessary. 15. What's your view on LGBTQ+ issues in Japan? There's a disconnect I see within the community here. There's a small, vocal group doing incredibly important work, pushing for rights and visibility. But sometimes, the focus is more on being digestible to straight audiences — presenting queerness as family-friendly, polished and easy to sympathize with. 16. What's the present situation of HIV awareness in Japan? Most guys I talk to know what PrEP (pre-exposure prophylaxis, a medication to prevent HIV infection) is. The message of U=U (an undetectable viral load equals untransmittable HIV) is more visible too. But PrEP is still not covered by national health insurance. Routine HIV testing still isn't normalized. We also need more mental health care. If prevention is neglected, we need support after diagnosis. You can't ignore people on both ends. 17. Do you face any discrimination in your daily life as an openly gay man in Japan? The fact that my human rights as a queer individual aren't recognized means I'm facing discrimination every day, whether it's obvious or not. 18. What do you think about Tokyo Rainbow Pride finally moving to June, in line with the rest of the world? I always thought it was kind of strange that it wasn't. Maybe it was because June is the rainy season here. The upside was that it added to Tokyo's eccentricity. But in terms of global visibility, aligning with the rest of the world makes sense. 19. What are your plans or projects for Pride Month this year? I'm hosting a lip-sync battle featuring Miss Grand Japan contestants at fancyHIM (a bar in Shinjuku Ni-chome). I've been one of the judges since 2018. I'm also doing a diversity, equity and inclusion workshop at (the hotel) W Osaka. I've been doing this with W every June. W Union Square was kind of a haven for us nightlife gays in New York. 20. What does Pride mean to you? When I was younger, Pride meant the NYC Pride parade. By the time the parade ended at Stonewall, I'd be making out with someone. But as I got older, I learned that Stonewall was the place where it all began. That's when Pride started to mean something deeper. Pride is respect for those who walked so we could run — or make out with boys in the street without fear.
RNZ News
3 days ago
- General
- RNZ News
'HIV should not be a death sentence in Fiji' - call for testing amid outbreak
Photo: 123RF Fiji's Minister for Health & Medical Services has revealed the latest HIV numbers in the country to a development partner roundtable on the country's response. There were 490 new HIV cases from October - December last year, bringing the 2024 total to 1583. "Included in this number are 32 newborns diagnosed with HIV acquired through mother-to-child transmission," Dr Atonio Rabici Lalabalavu said. Fiji declared an outbreak of the disease in January. The Fiji Sun reported around 115 HIV-related deaths in the January-September 2024 period. Fiji's Central Division reported 1100 new cases in 2024, with 427 in the Western Division and 50 in the Northern Division. Of the newly recorded cases, less than half - 770 - have been successfully linked to care, of which 711 have been commenced on antiretroviral therapy (ART). Just over half were aged in their twenties, and 70 percent of cases were male. Dr Lalabalavu said the increase in HIV cases is also seeing an increase in tuberculosis and HIV co-infection, with 160 individuals in a year. He said the ministry strongly encourages individuals to get tested, know their status, and if it is positive, seek treatment. Atonio Lalabalavu Photo: Facebook / Ministry of Health & Medical Services And if it is negative, to maintain that negative status. "I will reiterate what I have said before to all Fijians - HIV should not be a death sentence in Fiji." In the Western Pacific, the estimated number of people living with HIV (PLHIV) reached 1.9 million in 2020, up from 1.4 million in 2010. At the time, the World Health Organisation said over the previous two decades, HIV prevalence in the Western Pacific had remained low at 0.1 percent. However, the low prevalence in the general population masked high levels of HIV infection among key populations.
Yahoo
10-05-2025
- Business
- Yahoo
HIV Diagnostics Market Projected to Hit USD 1.80 Billion by 2032, Driven by Rising Global Testing Rates and Technological Advancements
Increasing awareness, improved healthcare access, and next-gen diagnostic tools fuel steady 5.10% CAGR growth in the HIV diagnostics market through 2032. Austin, May 10, 2025 (GLOBE NEWSWIRE) -- HIV Diagnostics Market Size Analysis: According to SNS Insider, the HIV Diagnostics Market was valued at USD 1.15 billion in 2023 and is set to reach USD 1.80 billion by 2032, growing at a CAGR of 5.10% during the forecast period of 2024–2032 The need for more rapid and readily accessible diagnostic tests has significantly increased as the global HIV count continues to rise. Advances in technology, improved healthcare facilities, and an increased focus on early diagnosis and prevention are largely responsible for this growth. As public support for healthcare grows, the market for HIV diagnostics will evolve substantially in most nations, especially in Asia-Pacific and North a Sample Report of HIV Diagnostics Market@ The U.S. HIV diagnostics market was valued at USD 0.20 billion in 2023 and is expected to reach USD 0.27 billion by the year 2032. This reflects a 3.36% CAGR. Increased diagnosis rates of HIV, increased awareness, and the embrace of improved diagnostic technology are largely to be blamed for this phenomenon. Innovations like in-home HIV diagnostic kits and point-of-care testing facilities keep the United States' market ahead of others in this regard. Major Players Analysis Listed in this Report are: Alere Inc.: Determine HIV-1/2 Ag/Ab Combo Abbott: ARCHITECT HIV Ag/Ab Combo Assay Bristol-Myers Squibb Company: Sustiva (efavirenz) Janssen Global Services, LLC: Prezista (darunavir) Gilead Sciences, Inc.: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV Healthcare: Tivicay (dolutegravir), Triumeq (abacavir/dolutegravir/lamivudine) BD (Becton, Dickinson and Company): BD FACSPresto System Beckman Coulter, Inc.: Access HIV Combo Assay PointCare: PointCare NOW System F. Hoffmann-La Roche Ltd.: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test Siemens Healthcare GmbH: ADVIA Centaur HIV Ag/Ab Combo Assay QIAGEN: artus HIV-1 QS-RGQ Kit OraSure Technologies: OraQuick In-Home HIV Test DiaSorin: LIAISON XL murex HIV Ab/Ag HIV Diagnostics Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.15 billion Market Size by 2032 US$ 1.80 billion CAGR CAGR of 5.10% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: Comprising a market share of 45.5%, the consumables sector led the HIV diagnostics market in 2023. The great demand for consumable items, reagents, and diagnostic kits used in HIV testing accounts for the predominance of this category. Consumables remain the main source of income, even with the rising number of diagnostic treatments carried out. Conversely, the sector of software and services is predicted to increase the most since the increasing acceptance of digital platforms and AI-based diagnostic tools enhances patient management and testing accuracy, thereby improving the segment. By Mode: With 90.9% of the market share in 2023, the category of laboratory-based testing kept its leading place. Given that laboratory-based tests—which are regarded as the gold standard for HIV diagnosis—have great accuracy and dependability, their supremacy results mostly from their On the other hand, the segment of self-testing is predicted to rise most since need for privacy and convenience lets people test for HIV in the comfort of their homes. The broad availability of at-home testing kits and a move toward decentralization in healthcare services promote this trend. By Test Type: With a 53.6% share of income, the segment of the antibody tests dominated the test category in 2023. The most often used HIV diagnostic test, the antibody tests, are the reason behind this supremacy since they produce consistent and accurate findings in HIV infection detection. Given its rising use in both clinical environments and at-home testing options, where it is considered the first line of HIV detection, the antibody test segment is also expected to increase the most. By End Use: The biggest end-use category in the HIV diagnostics market, the diagnostic labs segment, produced 50.4% of market revenue in 2023. HIV testing is mostly dependent on diagnostic labs since they can offer accurate, high-throughput testing. Driven by the growing availability and simplicity of home testing kits, the sector in home settings is predicted to develop fastest. In areas with high HIV prevalence and restricted access to healthcare infrastructure, this trend is especially noteworthy. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ HIV Diagnostics Market Segmentation By Product Consumables Instruments Software and Services By Mode Self-test Lab-based By Test type Antibody Test HIV-1 Screening Tests HIV-1 Antibody Confirmatory Tests HIV-2 & Group O Diagnostic Tests Viral load test CD4 test Others By End Use Diagnostic Laboratories Hospitals & Clinics Home Settings Recent Developments in HIV Diagnostics In November 2024, Egypt and the Global Fund signed a Framework Agreement aimed at strengthening health systems and improving HIV and tuberculosis response efforts while addressing the ongoing impact of COVID-19. UNDP will coordinate efforts with the Ministry of Health and civil society organizations to enhance HIV prevention and diagnostic services. In April 2024, Cepheid received WHO prequalification for its Xpert HIV-1 Qual XC test. This point-of-care diagnostic test enables early HIV detection in infants using dried blood spots and whole blood samples, thus enhancing accessibility and accuracy in HIV diagnostics, especially in resource-limited settings. In January 2024, Abbott launched the ARCHITECT HIV Ag/Ab Combo test, which provides reliable and rapid detection of HIV infection by identifying both HIV antibodies and antigens. This test aims to improve diagnostic accuracy and accelerate HIV detection in clinical settings. In March 2024, Mylan announced the launch of its generic HIV self-testing kit, which is designed to provide users with a simple, accurate, and confidential method to test for HIV at home. The launch is part of Mylan's broader effort to improve access to affordable HIV diagnostics globally. In February 2024, Roche introduced a new fully automated system for HIV diagnostics, combining antigen and antibody testing for faster and more accurate results. This innovation is expected to improve efficiency in high-throughput testing labs. Regional Analysis North America dominated the HIV diagnostics market in 2023 due to the presence of leading healthcare providers and the high demand for advanced diagnostic solutions. Government initiatives, such as increased funding for HIV awareness and testing programs, have contributed to the market's dominance in the region. Furthermore, the region's well-established healthcare infrastructure and adoption of cutting-edge diagnostic technologies, including self-testing kits and at-home diagnostic tools, continue to drive market growth. Asia Pacific is expected to experience the highest growth from 2024 to 2032. The region has a large HIV-infected population, and increasing government and private sector efforts to combat the disease. Growing awareness, improved access to healthcare services, and the increasing adoption of advanced HIV diagnostics are driving this rapid growth. Statistical Insights and Trends Reporting In 2023, the global incidence of new HIV cases was approximately 1.5 million, with Sub-Saharan Africa accounting for the majority of new infections. North America accounted for the highest share of HIV testing prescriptions, with a growing shift toward self-testing and rapid diagnostic tests. North America and Europe dominated the HIV diagnostics device volume in 2023, while Asia Pacific is expected to show the highest volume growth due to increased testing and awareness. In 2023, government-funded HIV diagnostic programs accounted for 60% of global HIV testing efforts, with the remaining share split between commercial healthcare providers and out-of-pocket expenditures in low-income a Single-User PDF of HIV Diagnostics Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of HIV (2023) 5.2 HIV Testing and Diagnosis Rates (2023), by Region 5.3 HIV Diagnostic Test Volume, by Region (2020-2032) 5.4 Healthcare Spending on HIV Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023 5.5 Adoption of Advanced HIV Diagnostic Technologies (2023-2032) 5.6 Regulatory Approvals and Policy Impact on HIV Diagnostics (2023-2032) 6. Competitive Landscape 7. HIV Diagnostics Market by Product 8. HIV Diagnostics Market by Mode 9. HIV Diagnostics Market by Test type 10. HIV Diagnostics Market by End Use 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Reports: Point-of-Care Testing Market Analysis Molecular Diagnostics Market Forecast Immunoassay Analyzers Market Trends STD Diagnostics Market Outlook Rapid Medical Diagnostic Kits Market Overview About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
HIV Diagnostics Market Projected to Hit USD 1.80 Billion by 2032, Driven by Rising Global Testing Rates and Technological Advancements
Increasing awareness, improved healthcare access, and next-gen diagnostic tools fuel steady 5.10% CAGR growth in the HIV diagnostics market through 2032. Austin, May 10, 2025 (GLOBE NEWSWIRE) -- HIV Diagnostics Market Size Analysis: According to SNS Insider, the HIV Diagnostics Market was valued at USD 1.15 billion in 2023 and is set to reach USD 1.80 billion by 2032, growing at a CAGR of 5.10% during the forecast period of 2024–2032 The need for more rapid and readily accessible diagnostic tests has significantly increased as the global HIV count continues to rise. Advances in technology, improved healthcare facilities, and an increased focus on early diagnosis and prevention are largely responsible for this growth. As public support for healthcare grows, the market for HIV diagnostics will evolve substantially in most nations, especially in Asia-Pacific and North a Sample Report of HIV Diagnostics Market@ The U.S. HIV diagnostics market was valued at USD 0.20 billion in 2023 and is expected to reach USD 0.27 billion by the year 2032. This reflects a 3.36% CAGR. Increased diagnosis rates of HIV, increased awareness, and the embrace of improved diagnostic technology are largely to be blamed for this phenomenon. Innovations like in-home HIV diagnostic kits and point-of-care testing facilities keep the United States' market ahead of others in this regard. Major Players Analysis Listed in this Report are: Alere Inc.: Determine HIV-1/2 Ag/Ab Combo Abbott: ARCHITECT HIV Ag/Ab Combo Assay Bristol-Myers Squibb Company: Sustiva (efavirenz) Janssen Global Services, LLC: Prezista (darunavir) Gilead Sciences, Inc.: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV Healthcare: Tivicay (dolutegravir), Triumeq (abacavir/dolutegravir/lamivudine) BD (Becton, Dickinson and Company): BD FACSPresto System Beckman Coulter, Inc.: Access HIV Combo Assay PointCare: PointCare NOW System F. Hoffmann-La Roche Ltd.: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test Siemens Healthcare GmbH: ADVIA Centaur HIV Ag/Ab Combo Assay QIAGEN: artus HIV-1 QS-RGQ Kit OraSure Technologies: OraQuick In-Home HIV Test DiaSorin: LIAISON XL murex HIV Ab/Ag HIV Diagnostics Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.15 billion Market Size by 2032 US$ 1.80 billion CAGR CAGR of 5.10% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: Comprising a market share of 45.5%, the consumables sector led the HIV diagnostics market in 2023. The great demand for consumable items, reagents, and diagnostic kits used in HIV testing accounts for the predominance of this category. Consumables remain the main source of income, even with the rising number of diagnostic treatments carried out. Conversely, the sector of software and services is predicted to increase the most since the increasing acceptance of digital platforms and AI-based diagnostic tools enhances patient management and testing accuracy, thereby improving the segment. By Mode: With 90.9% of the market share in 2023, the category of laboratory-based testing kept its leading place. Given that laboratory-based tests—which are regarded as the gold standard for HIV diagnosis—have great accuracy and dependability, their supremacy results mostly from their On the other hand, the segment of self-testing is predicted to rise most since need for privacy and convenience lets people test for HIV in the comfort of their homes. The broad availability of at-home testing kits and a move toward decentralization in healthcare services promote this trend. By Test Type: With a 53.6% share of income, the segment of the antibody tests dominated the test category in 2023. The most often used HIV diagnostic test, the antibody tests, are the reason behind this supremacy since they produce consistent and accurate findings in HIV infection detection. Given its rising use in both clinical environments and at-home testing options, where it is considered the first line of HIV detection, the antibody test segment is also expected to increase the most. By End Use: The biggest end-use category in the HIV diagnostics market, the diagnostic labs segment, produced 50.4% of market revenue in 2023. HIV testing is mostly dependent on diagnostic labs since they can offer accurate, high-throughput testing. Driven by the growing availability and simplicity of home testing kits, the sector in home settings is predicted to develop fastest. In areas with high HIV prevalence and restricted access to healthcare infrastructure, this trend is especially noteworthy. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ HIV Diagnostics Market Segmentation By Product Consumables Instruments Software and Services By Mode Self-test Lab-based By Test type Antibody Test HIV-1 Screening Tests HIV-1 Antibody Confirmatory Tests HIV-2 & Group O Diagnostic Tests Viral load test CD4 test Others By End Use Diagnostic Laboratories Hospitals & Clinics Home Settings Recent Developments in HIV Diagnostics In November 2024, Egypt and the Global Fund signed a Framework Agreement aimed at strengthening health systems and improving HIV and tuberculosis response efforts while addressing the ongoing impact of COVID-19. UNDP will coordinate efforts with the Ministry of Health and civil society organizations to enhance HIV prevention and diagnostic services. In April 2024, Cepheid received WHO prequalification for its Xpert HIV-1 Qual XC test. This point-of-care diagnostic test enables early HIV detection in infants using dried blood spots and whole blood samples, thus enhancing accessibility and accuracy in HIV diagnostics, especially in resource-limited settings. In January 2024, Abbott launched the ARCHITECT HIV Ag/Ab Combo test, which provides reliable and rapid detection of HIV infection by identifying both HIV antibodies and antigens. This test aims to improve diagnostic accuracy and accelerate HIV detection in clinical settings. In March 2024, Mylan announced the launch of its generic HIV self-testing kit, which is designed to provide users with a simple, accurate, and confidential method to test for HIV at home. The launch is part of Mylan's broader effort to improve access to affordable HIV diagnostics globally. In February 2024, Roche introduced a new fully automated system for HIV diagnostics, combining antigen and antibody testing for faster and more accurate results. This innovation is expected to improve efficiency in high-throughput testing labs. Regional Analysis North America dominated the HIV diagnostics market in 2023 due to the presence of leading healthcare providers and the high demand for advanced diagnostic solutions. Government initiatives, such as increased funding for HIV awareness and testing programs, have contributed to the market's dominance in the region. Furthermore, the region's well-established healthcare infrastructure and adoption of cutting-edge diagnostic technologies, including self-testing kits and at-home diagnostic tools, continue to drive market growth. Asia Pacific is expected to experience the highest growth from 2024 to 2032. The region has a large HIV-infected population, and increasing government and private sector efforts to combat the disease. Growing awareness, improved access to healthcare services, and the increasing adoption of advanced HIV diagnostics are driving this rapid growth. Statistical Insights and Trends Reporting In 2023, the global incidence of new HIV cases was approximately 1.5 million, with Sub-Saharan Africa accounting for the majority of new infections. North America accounted for the highest share of HIV testing prescriptions, with a growing shift toward self-testing and rapid diagnostic tests. North America and Europe dominated the HIV diagnostics device volume in 2023, while Asia Pacific is expected to show the highest volume growth due to increased testing and awareness. In 2023, government-funded HIV diagnostic programs accounted for 60% of global HIV testing efforts, with the remaining share split between commercial healthcare providers and out-of-pocket expenditures in low-income a Single-User PDF of HIV Diagnostics Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of HIV (2023) 5.2 HIV Testing and Diagnosis Rates (2023), by Region 5.3 HIV Diagnostic Test Volume, by Region (2020-2032) 5.4 Healthcare Spending on HIV Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023 5.5 Adoption of Advanced HIV Diagnostic Technologies (2023-2032) 5.6 Regulatory Approvals and Policy Impact on HIV Diagnostics (2023-2032) 6. Competitive Landscape 7. HIV Diagnostics Market by Product 8. HIV Diagnostics Market by Mode 9. HIV Diagnostics Market by Test type 10. HIV Diagnostics Market by End Use 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Reports: Point-of-Care Testing Market Analysis Molecular Diagnostics Market Forecast Immunoassay Analyzers Market Trends STD Diagnostics Market Outlook Rapid Medical Diagnostic Kits Market Overview About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
